0000000000726109

AUTHOR

Maddalena Casale

showing 2 related works from this author

Transfusion Therapy in a Multi-Ethnic Sickle Cell Population Real-World Practice. a Preliminary Data Analysis of Multicentre Survey

2018

Abstract Introduction. Despite the increasing of number of patients with Sickle Cell Disease (SCD) in Italy, due to multi-ethnic migratory phenomena, a large percentage of Caucasian sickle population is already present in Italy mainly with b-thal/HbS genotype. Red cell transfusion is one effective treatment for both acute and chronic complications of SCD, while hydroxycarbamide (HC) is used to reduce the frequency of painful vaso-occlusive crises (VOCs) and decrease the need for blood transfusion. Through the National Comprehensive Reference Centers for SCD, the Italian Society of Thalassemia and Hemoglobinopathies (SITE), in collaboration with the Society Italian Transfusion Medicine and I…

education.field_of_studyPediatricsmedicine.medical_specialtyBlood transfusionAnemiabusiness.industrymedicine.medical_treatmentImmunologyPopulationTransfusion medicineCell BiologyHematology030204 cardiovascular system & hematologymedicine.diseaseBiochemistryAcute chest syndromeSickle cell anemia03 medical and health sciencesRegimen0302 clinical medicine030220 oncology & carcinogenesismedicineTransfusion therapyeducationbusiness
researchProduct

Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major

2013

Transfusion and iron chelation treatment have significantly reduced morbidity and improved survival of patients with thalassemia major. However, cardiac disease continues to be the most common cause of death. We report the left-ventricular ejection fraction, determined by echocardiography, in one hundred sixtyeight patients with thalassemia major followed for at least 5 years who received continuous monotherapy with deferoxamine (N = 108) or deferiprone (N = 60). The statistical analysis, using the generalized estimating equations model, indicated that the group treated with deferiprone had a significantly better left-ventricular ejection fraction than did those treated with deferoxamine (c…

AdultMalemedicine.medical_specialtyIron OverloadHeart DiseasesPyridonesThalassemiaDeferoxamineIron Chelating AgentsVentricular Function Leftlaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawInternal medicineHumansMedicineDeferiproneIn patientYoung adultMolecular BiologyThalassemia major Left ventricular ejection fraction (LVEF) Deferiprone Deferoxamine Echocardiography ChelationRetrospective StudiesEjection fractionbusiness.industrybeta-ThalassemiaStroke VolumeRetrospective cohort studyCell BiologyHematologymedicine.diseaseDeferoxamineTreatment OutcomechemistryCardiologyMolecular MedicineFemalebusinessDeferipronemedicine.drug
researchProduct